VYNE
HEALTHCAREVYNE Therapeutics Inc
$0.67+0.00 (+0.53%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VYNE Today?
No stock-specific AI insight has been generated for VYNE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.28$1.96
$0.67
Fundamentals
Market Cap$22M
P/E Ratio—
EPS$-0.63
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume190K
Avg Volume (10D)—
Shares Outstanding33.4M
VYNE News
17 articles- SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBNBenzinga·Apr 1, 2026
- BC-Most Active StocksYahoo Finance·Dec 17, 2025
- VYNE Therapeutics and Yarrow Bioscience Announce Merger AgreementYahoo Finance·Dec 17, 2025
- VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance·Nov 6, 2025
- VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business UpdateYahoo Finance·Nov 6, 2025
- VYNE Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagYahoo Finance·Aug 18, 2025
- VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue EstimatesYahoo Finance·Aug 14, 2025
- VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business UpdateYahoo Finance·Aug 14, 2025
- Metagenomi (MGX) Reports Q2 Loss, Tops Revenue EstimatesYahoo Finance·Aug 12, 2025
- Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue EstimatesYahoo Finance·Aug 11, 2025
- Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass EstimatesYahoo Finance·Aug 6, 2025
- Here's Why VYNE Therapeutics (NASDAQ:VYNE) Must Use Its Cash WiselyYahoo Finance·Jul 31, 2025
- Sector Update: Health Care Stocks Decline in Late Afternoon TradingYahoo Finance·Jul 30, 2025
- VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental VitiligoYahoo Finance·Jul 30, 2025
- VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline ProgressYahoo Finance·Jul 11, 2025
- VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202Yahoo Finance·Jul 2, 2025
- VYNE Therapeutics First Quarter 2025 Earnings: Beats ExpectationsYahoo Finance·May 11, 2025
All 17 articles loaded
Price Data
Open$0.67
Previous Close$0.67
Day High$0.67
Day Low$0.65
52 Week High$1.96
52 Week Low$0.28
52-Week Range
$0.28$1.96
$0.67
Fundamentals
Market Cap$22M
P/E Ratio—
EPS$-0.63
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume190K
Avg Volume (10D)—
Shares Outstanding33.4M
About VYNE Therapeutics Inc
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—